Fulvestrant for the treatment of advanced breast cancer

Expert Review of Anticancer Therapy
Sophie A BlackburnKwok-Leung Cheung

Abstract

The current issues with endocrine therapy for treatment of advanced breast cancer include balance of efficacy of therapy versus tolerability as well as hormone resistance. The efficacy of fulvestrant, a selective oestrogen receptor degrader (SERD), has been demonstrated in hormone receptor positive patients previously untreated or treated with hormonal therapy. Areas covered: This article discusses the journey of fulvestrant licensing, its efficacy in combination with other endocrine therapies and the future role it may have within breast cancer treatment. Expert commentary: Within phase III trials, fulvestrant has demonstrated equivalent or improved clinical efficacy when compared with established endocrine agents. In the recent decade, fulvestrant has achieved licensing as a second line agent in non-operative advanced breast cancer at initially 250mg, increasing to 500mg. Presently, fulvestrant is licensed globally as first line endocrine management for advanced breast cancer in post-menopausal women. Early combination trials of fulvestrant and cyclin dependent kinase 4/6 inhibitors have demonstrated good clinical efficacy with improved progression free survival when compared to fulvestrant alone.

References

Mar 1, 1987·The Journal of Endocrinology·A E Wakeling, J Bowler
May 17, 1995·Journal of the National Cancer Institute·C K OsborneR I Nicholson
Jun 12, 1995·Annals of the New York Academy of Sciences·R I NicholsonB S Katzenellenbogen
Dec 11, 2002·Breast Cancer Research : BCR·Michael Baum
Nov 6, 2003·Journal of the National Cancer Institute·Clodia OsipoV Craig Jordan
Apr 20, 2004·British Journal of Cancer·J F R Robertson, M Harrison
Oct 28, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·I Vergote, P Abram
Jan 13, 2006·British Journal of Pharmacology·V Craig Jordan
Jun 24, 2006·The Oncologist·Kadri Altundag, Nuhad K Ibrahim
Dec 18, 2007·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·O E YoungJ M Dixon
Feb 27, 2009·BMJ : British Medical Journal·Adrian HarnettUNKNOWN Guideline Development Group
Aug 26, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John F R RobertsonMatthew J Ellis
May 25, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S OhnoS Noguchi
Sep 22, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Angelo Di LeoMiguel Martin
Oct 5, 2010·Annual Review of Medicine·C Kent Osborne, Rachel Schiff
Jul 8, 2011·Nature Reviews. Cancer·Elizabeth A MusgroveRobert L Sutherland
Jul 15, 2011·Journal of the National Cancer Institute·William F AndersonPhilip S Rosenberg
Aug 3, 2012·The New England Journal of Medicine·Rita S MehtaGabriel N Hortobagyi
Jul 17, 2015·International Journal of Cancer. Journal International Du Cancer·Amit AgrawalJulia M W Gee
Sep 16, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew J EllisJohn F R Robertson
Dec 14, 2016·The New England Journal of Medicine·Richard S FinnDennis J Slamon
Jun 6, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·George W SledgeAntonio Llombart-Cussac

❮ Previous
Next ❯

Citations

Sep 2, 2020·Cancers·Diego A PedrozaRajkumar Lakshmanaswamy
Nov 20, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Jessica CaciollaSilvia Gobbi

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2022 Meta ULC. All rights reserved